Please assess the completion status of the following clinical trial:

Trial Title: A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed melanoma of cutaneous origin~* Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resected~* BRAF V600 mutation status of the current primary tumor or involved lymph node determined to be positive using the cobas BRAF V600 mutation test~* Surgically rendered free of disease within 90 days of randomization~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Life expectancy of at least 5 years~* Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of melanoma, including interferon alpha-2b and pegylated interferon alpha-2b~* History of limb perfusion therapy~* History of radiotherapy for the treatment of melanoma~* Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment~* Family history of inherited colon cancer syndromes~* Known personal history of \>3 adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) \>2 centimeters (cm) in size~* History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions~* History of or current clinical, radiographic, or pathologic evidence of recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past~* History of local and/or regional and/or distant melanoma recurrence~* History or current radiographic or pathologic evidence of distant metastases~* History of clinically significant cardiac or pulmonary dysfunction~* Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatment~* Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 Vemurafenib (Type: EXPERIMENTAL): Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks
- Cohort 1 Placebo (Type: PLACEBO_COMPARATOR): Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks
- Cohort 2 Vemurafenib (Type: EXPERIMENTAL): Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks
- Cohort 2 Placebo (Type: PLACEBO_COMPARATOR): Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).